Xtane 25 - Pharmaceutical Grade

Exemestane, known commercially as Aromasin, was developed by Pharmacia and received FDA approval in 1999. It acts as an irreversible steroidal aromatase inhibitor and is chemically similar to formestane, but with greater potency. The drug is indicated for breast cancer in postmenopausal women after failure of tamoxifen therapy. It is marketed in tablet form and is globally accessible. Among athletes, Exemestane is often used off-label to combat estrogenic side effects associated with anabolic steroid use.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Xtane 25 by Pharmaceutical Grade, consult with your doctor or healthcare professional.